KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Intangibles (2018 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Change in Intangibles for 8 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Intangibles rose 207.93% year-over-year to $2.4 million, compared with a TTM value of $7.9 million through Dec 2025, down 33.83%, and an annual FY2025 reading of $7.9 million, down 33.83% over the prior year.
  • Change in Intangibles was $2.4 million for Q4 2025 at Biomarin Pharmaceutical, down from $5.3 million in the prior quarter.
  • Across five years, Change in Intangibles topped out at $15.6 million in Q4 2021 and bottomed at $266000.0 in Q2 2025.
  • Average Change in Intangibles over 5 years is $3.4 million, with a median of $1.9 million recorded in 2022.
  • The sharpest move saw Change in Intangibles tumbled 95.7% in 2022, then surged 2480.65% in 2024.
  • Year by year, Change in Intangibles stood at $15.6 million in 2021, then crashed by 95.7% to $671000.0 in 2022, then soared by 1059.31% to $7.8 million in 2023, then plummeted by 90.11% to $769000.0 in 2024, then skyrocketed by 207.93% to $2.4 million in 2025.
  • Business Quant data shows Change in Intangibles for BMRN at $2.4 million in Q4 2025, $5.3 million in Q3 2025, and $266000.0 in Q2 2025.